Companies › Novartis
108 active drug programs in 577 registered trials: 258 Phase 2, 165 Phase 1, 119 Phase 3, 35 Phase 4; Oncology, Neurology, Immunology, Cardiovascular; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Dabrafenib Serine/threonine-protein kinase B-raf inhibitor | BRAF | Phase 4 | Diffuse Astrocytoma; Melanoma; Differentiated Thyroid Cancer (DTC); Advanced Thyroid Cancer Patients Who Received Target Therapy … | Nov 2026 |
| Trametinib Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor | MAP2K2, MAP2K1 | Phase 4 | Diffuse Astrocytoma; Melanoma; Differentiated Thyroid Cancer (DTC); EGFR-mutant Non-small Cell Lung Cancer … | Nov 2026 |
| Inclisiran sodium PCSK9 mRNA rnai inhibitor | PCSK9 | Phase 4 | Hypercholesterolaemia; Plaque, Atherosclerotic; Coronary Heart Disease; Coronary Artery Disease … | Nov 2026 |
| Lutetium Lu-177 Vipivotide Tetraxetan (AAA617) Glutamate carboxypeptidase II binding agent | FOLH1 | Phase 4 | Prostate Cancer; Prostatic Neoplasms; Oligometastatic Prostate Cancer (OMPC); Metastatic Castration Resistant Prostate Cancer (mCRPC) … | Dec 2026 |
| Ribociclib (LEE011) Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 6 inhibitor | CDK4, CDK6 | Phase 4 | Metastatic Breast Cancer; Early Breast Cancer; Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies; Breast Cancer … | Dec 2026 |
| everolimus FK506-binding protein 1A inhibitor | FKBP1A | Phase 4 | Renal Angiomyolipoma; Tuberous Sclerosis Complex; Advanced Breast Cancer; Renal Cell Carcinoma … | Dec 2026 |
| Ceritinib (LDK378) ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor | ALK, EML4, NPM1 | Phase 4 | ALK Positive Malignancies; ALK-positive NSCLC; Neuroblastoma; ALK Positive … | Apr 2027 |
| Ofatumumab B-lymphocyte antigen CD20 binding agent | MS4A1 | Phase 4 | Multiple Sclerosis; Relapsing-Remitting Multiple Sclerosis; Relapsing Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS) … | Apr 2027 |
| Asciminib Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 4 | Chronic Myelogenous Leukemia; Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive; Philadelphia Chromosome-Positive Chronic Myeloid Leukemia; Chronic Myelogenous Leukemia - Chronic Phase … | Sep 2027 |
| Fingolimod Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent | S1PR5, S1PR2, S1PR4, S1PR3, S1PR1 | Phase 4 | Multiple Sclerosis; Diabetes Mellitus, Type 2; Non Small Cell Lung Cancer | Sep 2027 |
| Secukinumab Interleukin 17A inhibitor | IL17A | Phase 4 | Non-radiographic Axial Spondyloarthritis; Hidradenitis Suppurativa (HS); Autoimmunity, Inflammation; Polymyalgia Rheumatica … | Feb 2028 |
| ETNA-ProgMS Software as a Medical Device (SaMD) for tracking eye movements as biomarkers of neurologic | – | Phase 4 | Relapsing Remitting Multiple Sclerosis (RRMS) | Nov 2028 |
| Crizanlizumab (SEG101) P-selectin blocker | SELP | Phase 4 | Sickle Cell Disease; Sickle Cell Disease (SCD); Advanced Glioblastoma | Jul 2029 |
| panobinostat Histone deacetylase inhibitor | HDAC (class I/II) | Phase 4 | Primary Myelofibrosis; Sickle Cell Disease | Apr 2032 |
| Onasemnogene Abeparvovec-brve (ITVISMA®) Adeno-associated virus serotype 9 (AAV9) delivering SMN1 gene | SMN1 | Phase 4 | Spinal Muscular Atrophy | May 2032 |
| Pelabresib Bromodomain and extra-terminal motif (BET) inhibitor | BRD2, BRD4, BRDT, BRD3 | Phase 3 | Hematologic Malignancy; Myelofibrosis; Primary Myelofibrosis (PMF); Healthy Participants … | Nov 2026 |
| Iptacopan Complement factor B inhibitor | CFB | Phase 3 | C3G; Generalized Myasthenia Gravis; Paroxysmal Nocturnal Hemoglobinuria; Atypical Hemolytic Uremic Syndrome … | Dec 2026 |
| JDQ443 KRAS G12C inhibitor | KRAS | Phase 3 | Non-Small Cell Lung Cancer; Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation; KRAS G12C Mutant Solid Tumors; NSCLC | Jan 2027 |
| Alpelisib (BYL719) PI3-kinase p110-alpha subunit inhibitor | PIK3CA | Phase 3 | Breast Cancer; Advanced HER2+Breast Cancer; Breast Neoplasms; Advanced Breast Cancer … | Jan 2027 |
| remibrutinib (LOU064) Bruton's tyrosine kinase (BTK) inhibitor | BTK | Phase 3 | Chronic Spontaneous Urticaria (CSU); Hidradenitis Suppurativa; Chronic Spontaneous Urticaria; Generalized Myasthenia Gravis … | Feb 2027 |
| Ianalumab (VAY736) Tumor necrosis factor receptor superfamily member 13C binding agent | TNFRSF13C | Phase 3 | Systemic Lupus Erythematosus; Sjogren Syndrome; Lupus Nephritis; Primary Immune Thrombocytopenia … | Mar 2027 |
| Tisagenlecleucel (CTL019) B-lymphocyte antigen CD19 binding agent | CD19 | Phase 3 | B-cell Acute Lymphoblastic Leukemia; Follicular Lymphoma (FL); Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program; B-Cell Acute Lymphoblastic Leukemia … | Mar 2027 |
| Zigakibart (BION-1301, FUB523) | – | Phase 3 | IgA Nephropathy; Kidney Diseases; Immunoglobulin A Nephropathy (IgAN) | Aug 2027 |
| NIO752 antisense oligonucleotide | – | Phase 3 | Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS); Alzheimer Disease | Sep 2027 |
| Indacaterol (QVM149) Beta-2 adrenergic receptor agonist | ADRB2 | Phase 3 | Asthma | Feb 2028 |
| Pelacarsen (TQJ230) LPA mRNA antisense inhibitor | LPA | Phase 3 | Atherosclerotic Cardiovascular Disease (ASCVD); Hyperlipoproteinemia (a); Cardiovascular Disease and Lipoprotein(a); Atherosclerotic Cardiovascular Disease … | Feb 2028 |
| Atrasentan Endothelin receptor ET-A antagonist | EDNRA | Phase 3 | IgA Nephropathy; Berger Disease | Apr 2028 |
| Omalizumab Ig epsilon chain C region inhibitor | IGHE | Phase 3 | Chronic Spontaneous Urticaria; Food Allergy; Asthma; Chronic Sinusitis … | May 2028 |
| AAA817 | – | Phase 3 | Prostate Cancer | Jun 2028 |
| Enzalutamide Androgen Receptor antagonist | AR | Phase 3 | Prostate Cancer; Castration-Resistant Prostatic Cancer; Prostatic Neoplasms; Castration-Resistant Prostate Carcinoma … | Sep 2028 |
| [177Lu]Lu-DOTA-TATE SSTR2-targeted radioligand therapy with lutetium-177 | SSTR2 | Phase 3 | Somatostatin Receptor Positive (SSTR+); Metastatic Neuroendocrine Prostate Cancer | Dec 2028 |
| Votoplam HTT-lowering antisense oligonucleotide | HTT | Phase 3 | Huntington Disease | Jul 2029 |
| Siponimod Sphingosine 1-phosphate receptor Edg-1 agonist | S1PR1 | Phase 3 | Multiple Sclerosis (MS); Alzheimer Disease | Feb 2031 |
| onasemnogene abeparvovec Survival motor neuron protein exogenous gene | SMN2, SMN1 | Phase 3 | Spinal Muscular Atrophy (SMA) | Apr 2031 |
| Onasemnogene Abeparvovec Survival motor neuron protein exogenous gene | SMN2, SMN1 | Phase 3 | Spinal Muscular Atrophy Type I | Dec 2035 |
| Eltrombopag Thrombopoietin receptor agonist | MPL | Phase 2 | Myelodysplastic Syndromes | Dec 2026 |
| Fulvestrant Estrogen receptor alpha antagonist; Estrogen receptor degrader | ESR1 | Phase 2 | Advanced Breast Cancer; Breast Cancer | Dec 2026 |
| [177Lu]Lu-PSMA-617 PSMA-targeted radioligand therapy with lutetium-177 | FOLH1, GRPR | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Neuroendocrine Prostate Cancer; Metastatic Castration-resistant Prostate Cancer | Jan 2027 |
| JSB462 (luxdegalutamide) GLP-1 receptor agonist | GLP1R | Phase 2 | Prostatic Cancer, Castration-Resistant; Metastatic Hormone-sensitive Prostate Cancer; Metastatic Prostate Cancer (mCRPC); Progressive Metastatic Castrate Resistant Prostate Cancer | Jan 2027 |
| LTT462 RAF inhibitor | – | Phase 2 | Melanoma | Feb 2027 |
| Naporafenib (LXH254) B-raf/RAF proto-oncogene serine/threonine-protein kinase inhibitor | RAF1, BRAF | Phase 2 | Melanoma; EGFR-mutant Non-small Cell Lung Cancer | Feb 2027 |
| Cipargamin (KAE609) P-type ATPase inhibitor | PFATP4 | Phase 2 | Uncomplicated Plasmodium Falciparum Malaria | Feb 2027 |
| KLU156 Fixed-dose combination of KAF156 + lumefantrine | – | Phase 2 | Uncomplicated Plasmodium Falciparum Malaria | Feb 2027 |
| PKN605 | – | Phase 2 | Atrial Fibrillation; Participants With Moderate and Severe Renal Impairment and Healthy Participants | Mar 2027 |
| EDI048 | – | Phase 2 | Cryptosporidiosis | Mar 2027 |
| Arumakimig (MAS825) | – | Phase 2 | Hidradenitis Suppurativa; Still´s Disease; VEXAS Syndrome; NLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 Mutations | Apr 2027 |
| DII235 Lipoprotein(a) lowering agent | – | Phase 2 | Lipoprotein Disorder | Apr 2027 |
| QCZ484 KRAS G12C inhibitor | – | Phase 2 | Hypercholesterolaemia; Hypertension; Hypertension (HTN) | Apr 2027 |
| GIA632 GPCR agonist | – | Phase 2 | Atopic Dermatitis; Non-segmental Vitiligo; Cutaneous Lichen Planus | May 2027 |
| Spartalizumab (PDR001) Programmed cell death protein 1 antagonist | PDCD1 | Phase 2 | Myelodysplastic Syndromes; Carcinoma, Non-Small-Cell Lung; Advanced Solid Tumors; Squamous Cell Anal Carcinoma … | Jun 2027 |
| Rapcabtagene autoleucel | – | Phase 2 | Lupus Erythematosus, Systemic; Scleroderma, Diffuse; Idiopathic Inflammatory Myopathies; ANCA Associated Vasculitis (AAV) … | Jun 2027 |
| Capmatinib Hepatocyte growth factor receptor inhibitor | MET | Phase 2 | Advanced Solid Tumors Which Are cMET-dependent; EGFR-mutant Non-small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; Solid Tumour | Jul 2027 |
| Nazartinib Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor | EGFR | Phase 2 | Advanced Solid Tumors Which Are cMET-dependent; EGFR-mutant Non-small Cell Lung Cancer | Jul 2027 |
| EYU688 | – | Phase 2 | Dengue | Jul 2027 |
| LXE408 | – | Phase 2 | Chagas Disease | Jul 2027 |
| GXV813 | – | Phase 2 | Schizophrenia | Jul 2027 |
| Glycopyrronium bromide Muscarinic acetylcholine receptor M3 antagonist; Muscarinic acetylcholine receptor M1 antagonist | CHRM3, CHRM1 | Phase 2 | Asthma; Post-Dural Puncture Headache | Jul 2027 |
| YMI024 | – | Phase 2 | Coronary Artery Disease | Aug 2027 |
| Sabatolimab (MBG453) Hepatitis A virus cellular receptor 2 inhibitor | HAVCR2 | Phase 2 | Myelodysplastic Syndromes | Feb 2028 |
| VHB937 | – | Phase 2 | Amyotrophic Lateral Sclerosis (ALS); Alzheimer's Disease | Jul 2028 |
| GHZ339 | – | Phase 2 | Atopic Dermatitis | Nov 2028 |
| DDY391 Unclear - mechanism not stated in registry text | – | Phase 2 | Moderate to Severe Psoriatic Arthritis; Sjögren's Disease | Dec 2028 |
| Midostaurin Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor | FLT3, KIT, PDGFRB, PDGFRA, PRKD3 | Phase 2 | FLT3-mutated Acute Myeloid Leukemia; AML/MDS; Acute Myeloid Leukemia | May 2029 |
| FWY003 | – | Phase 2 | Geographic Atrophy Secondary to Age-related Macular Degeneration | Aug 2029 |
| INE963 | – | Phase 2 | Uncomplicated Plasmodium Falciparum Malaria | – |
| Iscalimab (CFZ533) Tumor necrosis factor receptor superfamily member 5 inhibitor | CD40 | Phase 2 | Hidradenitis Suppurativa | – |
| LYS006 Bruton's tyrosine kinase (BTK) inhibitor | – | Phase 2 | Hidradenitis Suppurativa | – |
| HJB647 | – | Phase 1 | Heart Failure With Reduced Ejection Fraction; Elevated Blood Pressure | Dec 2026 |
| [177Lu]Lu-NeoB GRPR-targeted radioligand therapy | GRPR | Phase 1 | Breast Cancer; Newly Diagnosed and Recurrent Glioblastoma | Dec 2026 |
| PIT565 CD19-directed T cell engager | – | Phase 1 | B-cell Non-Hodgkin Lymphoma (B-NHL); Systemic Lupus Erythematosus, SLE; Rheumatoid Arthritis | Jan 2027 |
| IAG933 YAP/TAZ pathway inhibitor | – | Phase 1 | Mesothelioma | Jan 2027 |
| Batoprotafib (TNO155) Protein-tyrosine phosphatase 2C inhibitor | PTPN11 | Phase 1 | KRAS G12C Mutant Solid Tumors | Jan 2027 |
| DFV890 | – | Phase 1 | Myeloid Diseases | Feb 2027 |
| Lutetium Oxodotreotide Somatostatin receptor binding agent | SSTR5, SSTR2, SSTR4, SSTR1, SSTR3 | Phase 1 | Glioblastoma; Extensive Stage Small Cell Lung Cancer | May 2027 |
| ARV-766 Androgen receptor antagonist | AR | Phase 1 | Prostate Cancer Metastatic | May 2027 |
| DKY709 Novel immunomodulatory agent | – | Phase 1 | Carcinoma, Non-Small-Cell Lung | Jun 2027 |
| [68Ga]Ga-NeoB Gallium-68 radiopharmaceutical PET imaging agent targeting neurotensin receptors | – | Phase 1 | Newly Diagnosed and Recurrent Glioblastoma | Aug 2027 |
| HRO761 | – | Phase 1 | MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers | Aug 2027 |
| DYP688 GNAQ/GNA11 inhibitor | GNAQ, GNA11 | Phase 1 | Metastatic Uveal Melanoma | Oct 2027 |
| KFA115 Immunomodulatory agent | – | Phase 1 | Carcinoma, Non-Small-Cell Lung | Oct 2027 |
| 177Lu-FAP-2286 FAP-targeted peptide radioligand (177Lu-labeled) | FAP | Phase 1 | Solid Tumor | Dec 2027 |
| 68Ga-DFC413 Radioimaging agent | – | Phase 1 | Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Jan 2028 |
| 68Ga-NNS309 Radioimaging agent | – | Phase 1 | Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Jan 2028 |
| OJR520 | – | Phase 1 | Chronic Kidney Disease | Jan 2028 |
| DCY636 unclear mechanism | – | Phase 1 | Dermatitis, Atopic | Jan 2028 |
| EDK060 | – | Phase 1 | Charcot-Marie-Tooth Disease, Type 1A | Feb 2028 |
| ITU512 Fetal hemoglobin (HbF) inducer | – | Phase 1 | Sickle Cell Disease | May 2028 |
| [68Ga]Ga-DWJ155 Radioligand imaging agent | – | Phase 1 | Advanced Gastroesophageal Adenocarcinoma; Breast Neoplasms; Breast Cancer | Jun 2028 |
| AMO959 DNA Damage Response inhibitor | – | Phase 1 | PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | Jul 2028 |
| ECI830 | – | Phase 1 | Advanced HR+/HER2- Breast Cancer | Sep 2028 |
| LTP001 | – | Phase 1 | Healthy Volunteers, Pulmonary Arterial Hypertension | Nov 2028 |
| [177Lu]Lu-DFC413 Therapeutic radiopharmaceutical (lutetium-177-labeled) | – | Phase 1 | Pancreatic Ductal Adenocarcinoma | May 2029 |
| [68Ga]Ga-NNS309 Diagnostic radiopharmaceutical (gallium-68-labeled) | – | Phase 1 | Pancreatic Ductal Adenocarcinoma | May 2029 |
| Opnurasib KRAS inhibitor | KRAS | Phase 1 | Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer | Jun 2029 |
| YTB323 CAR-T cell therapy targeting muscle-specific kinase (MuSK) | – | Phase 1 | Generalized Myasthenia Gravis | Oct 2029 |
| Tulmimetostat (DZR123, CPI-0209) Dual EZH1/EZH2 inhibitor | EZH1, EZH2 | Phase 1 | Progressive Metastatic Castrate Resistant Prostate Cancer; Advanced Solid Tumor; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Mycosis Fungoides | Nov 2029 |
| INR731 | – | Phase 1 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Jun 2030 |
| IDH305 Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor | IDH1 | Phase 1 | Advanced Malignancies That Harbor IDHR132 Mutations | Oct 2030 |
| [177Lu]Lu-NNS309 Radioligand therapy (radiotherapeutic agent) | – | Phase 1 | Pancreatic Ductal Adenocarcinoma | Jan 2031 |
| DJI136 DLL3-targeted CAR-T therapy | DLL3 | Phase 1 | Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Mar 2031 |
| [225Ac]Ac-PSMA-R2 Alpha-emitting radiopharmaceutical targeting PSMA; 225Ac-labeled PSMA ligand | FOLH1 | Phase 1 | Prostate Cancer | Mar 2031 |
| GVV858 | – | Phase 1 | Advanced HR+/HER2- Breast Cancer | May 2031 |
| DFT383 Autologous hematopoietic stem cell (HSC) gene therapy | – | Phase 1 | Nephropathic Cystinosis | May 2031 |
| [111In]In-ETN029 Indium-111 labeled imaging agent targeting DLL3 | DLL3 | Phase 1 | Small Cell Lung Carcinoma | Aug 2031 |
| [225Ac]Ac-ETN029 Alpha-emitting radioligand targeting DLL3 | DLL3 | Phase 1 | Small Cell Lung Carcinoma | Aug 2031 |
| [177Lu]Lu-DWJ155 Radioligand therapy (Lu-177 labeled) | – | Phase 1 | Breast Cancer | May 2032 |
| IEV407 | – | Phase 1 | Advanced HR+/HER2- Breast Cancer | Jun 2032 |
| OTQ923 Genome-edited autologous hematopoietic stem and progenitor cells (HSPC) | – | Phase 1 | Sickle Cell Disease | Jan 2039 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03814746 | Crizanlizumab (SEG101) | Phase 3 | Sickle Cell Disease (SCD) | Hematology | Aug 2022 |
| NCT03753243 | Enzalutamide | Phase 2 | Prostate Cancer | Oncology | Sep 2022 |
| NCT04689828 | Lutetium Lu-177 Vipivotide Tetraxetan (AAA617) | Phase 3 | Prostatic Neoplasms | Oncology | Oct 2022 |
| NCT04430192 | Lutetium Lu-177 Vipivotide Tetraxetan (AAA617) | Phase 1 | Prostatic Neoplasms | Oncology | Dec 2022 |
| NCT02881242 | Trametinib | Phase 2 | Hormone-Resistant Prostate Cancer | Oncology | Jan 2024 |
| NCT04573920 | Atrasentan | Phase 2 | IgA Nephropathy | Genitourinary | Jul 2024 |
| NCT01990196 | Trametinib | Phase 2 | Prostate Cancer | Oncology | Sep 2024 |
| NCT01990196 | Enzalutamide | Phase 2 | Prostate Cancer | Oncology | Sep 2024 |
| NCT05445843 | JDQ443 | Phase 2 | Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation | Oncology | Nov 2024 |
| NCT03827798 | Ianalumab (VAY736) | Phase 2 | Hidradenitis Suppurativa | Immunology | Dec 2024 |
| NCT03827798 | remibrutinib (LOU064) | Phase 2 | Hidradenitis Suppurativa | Immunology | Dec 2024 |
| NCT03827798 | Arumakimig (MAS825) | Phase 2 | Hidradenitis Suppurativa | Immunology | Dec 2024 |
| NCT03827798 | Iscalimab (CFZ533) | Phase 2 | Hidradenitis Suppurativa | Immunology | Dec 2024 |
| NCT03827798 | LYS006 | Phase 2 | Hidradenitis Suppurativa | Immunology | Dec 2024 |
| NCT03944434 | Ribociclib (LEE011) | Phase 2 | Breast Cancer | Oncology | Dec 2024 |
| NCT03874884 | Lutetium Lu-177 Vipivotide Tetraxetan (AAA617) | Phase 1 | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Oncology | May 2025 |
| NCT06338293 | Inclisiran sodium | Phase 4 | Coronary Artery Disease | Cardiovascular | Jun 2025 |
| NCT04762979 | Alpelisib (BYL719) | Phase 2 | Hormone Receptor Positive Breast Carcinoma | Oncology | Oct 2025 |
| NCT06444113 | Ofatumumab | Phase 4 | Multiple Sclerosis | Neurology | Feb 2026 |
| NCT04343885 | Lutetium Lu-177 Vipivotide Tetraxetan (AAA617) | Phase 2 | Metastatic Hormone Naive Prostate Cancer | Oncology | Mar 2026 |
| NCT05268289 | Iptacopan | Phase 2 | Lupus Nephritis | Immunology | Mar 2026 |
| NCT03285412 | Ribociclib (LEE011) | Phase 2 | Breast Cancer | Oncology | Apr 2026 |
| NCT05504694 | Ofatumumab | Phase 1 | Neuromyelitis Optica Spectrum Disorder | Neurology | Apr 2026 |
| NCT05750628 | INE963 | Phase 2 | Uncomplicated Plasmodium Falciparum Malaria | Infectious disease | Jun 2026 |
| NCT05750628 | Cipargamin (KAE609) | Phase 2 | Uncomplicated Plasmodium Falciparum Malaria | Infectious disease | Jun 2026 |
| NCT05750628 | KLU156 | Phase 2 | Uncomplicated Plasmodium Falciparum Malaria | Infectious disease | Jun 2026 |
| NCT02446444 | Enzalutamide | Phase 3 | Prostatic Neoplasms | Oncology | Jun 2026 |
| NCT06372821 | NIO752 | Phase 1 | Alzheimer Disease | Neurology | Jul 2026 |
| NCT03091257 | Dabrafenib | Phase 1 | Multiple Myeloma | Oncology | Jul 2026 |
| NCT03091257 | Trametinib | Phase 1 | Multiple Myeloma | Oncology | Jul 2026 |
| NCT01087554 | everolimus | Phase 1 | Advanced Cancer | Oncology | Aug 2026 |
| NCT05230537 | Iptacopan | Phase 2 | Age-Related Macular Degeneration | Ophthalmology | Aug 2026 |
| NCT05303285 | Secukinumab | Phase 4 | Ankylosing Spondylitis (AS) | Immunology | Aug 2026 |
| NCT05132075 | JDQ443 | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Sep 2026 |
| NCT05358249 | JDQ443 | Phase 1 | KRAS G12C Mutant Solid Tumors | Oncology | Sep 2026 |
| NCT06379217 | [177Lu]Lu-PSMA-617 | Phase 1 | Metastatic Neuroendocrine Prostate Cancer | Oncology | Oct 2026 |
| NCT06379217 | [177Lu]Lu-PSMA-617 | Phase 1 | Metastatic Neuroendocrine Prostate Cancer | Oncology | Oct 2026 |
| NCT06379217 | [177Lu]Lu-DOTA-TATE | Phase 1 | Metastatic Neuroendocrine Prostate Cancer | Oncology | Oct 2026 |
| NCT05252585 | everolimus | Phase 4 | Renal Angiomyolipoma | Genitourinary | Oct 2026 |
| NCT03090165 | Ribociclib (LEE011) | Phase 1 | Triple Negative Breast Cancer | Oncology | Oct 2026 |
| NCT06894511 | Lutetium Lu-177 Vipivotide Tetraxetan (AAA617) | Phase 2 | Metastatic Castration Resistant Prostate Cancer (mCRPC) | Oncology | Oct 2026 |
| NCT05360446 | Inclisiran sodium | Phase 3 | Coronary Artery Disease | Cardiovascular | Oct 2026 |
| NCT03975829 | Dabrafenib | Phase 4 | Diffuse Astrocytoma | Oncology | Nov 2026 |
| NCT03975829 | Trametinib | Phase 4 | Diffuse Astrocytoma | Oncology | Nov 2026 |
| NCT07783503 | Pelabresib | Phase 1 | Healthy Participants | Other | Nov 2026 |
| NCT04097470 | Midostaurin | Phase 2 | AML/MDS | Oncology | Nov 2026 |
| NCT06501443 | Inclisiran sodium | Phase 4 | Hypercholesterolaemia | Cardiovascular | Nov 2026 |
| NCT05660083 | Alpelisib (BYL719) | Phase 2 | HER2-negative Breast Cancer | Oncology | Dec 2026 |
| NCT06852820 | Lutetium Lu-177 Vipivotide Tetraxetan (AAA617) | Phase 2 | Liver Cancer | Oncology | Dec 2026 |
| NCT06964958 | Lutetium Lu-177 Vipivotide Tetraxetan (AAA617) | Phase 2 | Renal Cell Carcinoma | Oncology | Dec 2026 |
| NCT06555237 | Trametinib | Phase 2 | Cardiomegaly | Cardiovascular | Dec 2026 |
| NCT04419402 | Enzalutamide | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | Oncology | Dec 2026 |
| NCT04797000 | Eltrombopag | Phase 2 | Myelodysplastic Syndromes | Hematology | Dec 2026 |
| NCT05081193 | Enzalutamide | Phase 2 | Prostate Cancer | Oncology | Dec 2026 |
| NCT07465653 | HJB647 | Phase 1 | Heart Failure With Reduced Ejection Fraction | Cardiovascular | Dec 2026 |
| NCT06004661 | Lutetium Lu-177 Vipivotide Tetraxetan (AAA617) | Phase 2 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Oncology | Dec 2026 |
| NCT03114527 | Ribociclib (LEE011) | Phase 2 | Soft Tissue Sarcoma | Oncology | Dec 2026 |
| NCT02712723 | Ribociclib (LEE011) | Phase 2 | Breast Cancer | Oncology | Dec 2026 |
| NCT05143229 | Alpelisib (BYL719) | Phase 1 | Breast Cancer | Oncology | Dec 2026 |
| NCT05340374 | Lutetium Lu-177 Vipivotide Tetraxetan (AAA617) | Phase 1 | Metastatic Castration-resistant Prostate Cancer | Oncology | Dec 2026 |
The 60 nearest readouts of 577 trials; the rest in the app.
Cash and short-term investments of $11.6bn on 2025-12-31; operating cash flow positive
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.